688050.SH
爱博医疗
SSE · Healthcare · Medical - Instruments & Supplies · CN
CNY 39.22
−3.11%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.5B | 1.5B | 1.4B | 951.2M | 579.5M |
| Cost of Revenue | 568.2M | 541.3M | 476.2M | 231.4M | 88.4M |
| Gross Profit | 955.5M | 941.4M | 933.8M | 719.8M | 491.1M |
| Operating Expenses | |||||
| R&D Expense | 88.1M | 95.7M | 107.2M | 93.6M | 66.0M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 193.9M | 189.7M | 170.9M | 115.0M | 68.5M |
| Selling & Marketing Expense | 264.3M | 257.6M | 199.0M | 180.3M | 108.0M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 584.8M | 580.7M | 508.5M | 406.8M | 248.6M |
| Cost and Expenses | 1.2B | 1.1B | 984.7M | 638.2M | 337.0M |
| Operating Income (EBIT) | 287.5M | 289.7M | 433.0M | 327.5M | 259.3M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 286.8M | 289.3M | 431.1M | 327.7M | 264.1M |
| Income Tax Expense | 50.3M | 48.7M | 44.0M | 41.6M | 36.8M |
| Bottom Line | |||||
| Net Income | 264.9M | 268.2M | 388.4M | 304.0M | 232.7M |
| Earnings from Cont. Ops | 236.6M | 240.6M | 387.1M | 286.1M | 227.2M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 264.9M | 268.2M | 388.4M | 304.0M | 232.7M |
| Per Share | |||||
| Basic EPS | CN¥1.38 | CN¥1.40 | CN¥2.05 | CN¥1.61 | CN¥2.21 |
| Diluted EPS | CN¥1.38 | CN¥1.40 | CN¥2.05 | CN¥1.60 | CN¥2.21 |
| Revenue Per Share | CN¥7.85 | CN¥7.74 | CN¥7.44 | CN¥5.04 | CN¥5.50 |
| Shares | |||||
| Basic Shares Outstanding | 194.1M | 191.6M | 189.5M | 188.8M | 105.3M |
| Diluted Shares Outstanding | 194.1M | 191.6M | 189.5M | 188.8M | 105.3M |
| Profitability Metrics | |||||
| EBITDA | — | 461.7M | 573.8M | 409.5M | 308.1M |
| D&A | — | 172.0M | 140.8M | 82.1M | 48.9M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026